1 minute treatment update

Treatment pearls in your chosen speciality or topic, as they are published, updated every 48 hours.
Last updated on 2024/02/23.





Int Wound J Feb. 2024.
Unique combination of hyaluronic acid and amino acids in the management of patients with a wide range of moderate-to-severe chronic wounds: Evidence from international clinical practice.

Clinical trials confirm the effectiveness of the unique combination of hyaluronic acid and amino acids (Vulnamin®) in a range of wounds, but are these results replicated in real-world clinical practice? International experts presented their clinical experience with the use of the combination in difficult-to-treat wounds. The objective was to reach a consensus on how and when to use the unique combination products to provide a cost-effective, convenient option, in all healthcare settings that improves QoL for patients and their carers

 Pubmed Scholar sci-hub

Int Wound J Feb. 2024.
Unique combination of hyaluronic acid and amino acids in the management of patients with a range of moderate-to-severe chronic wounds: Evidence from international clinical trials.

Tissue regeneration and tissue repair are considered to be the fundamental activities of this unique combination of HA and amino acids that distinguishes it from other wound healing products. A review of trials over the last 15 years indicates distinct advantages of the unique combination of HA and amino acids, in terms of healing rate and induction of granulation tissue production compared with HA alone

 Pubmed Scholar sci-hub

J Pers Med 07 Feb. 2024.
Effectiveness and Safety of Biological Therapies in Very Severe Plaque Psoriasis: A Real-Life Retrospective Study.

Only two patients discontinued biologics due to complete remission, and mild AEs were reported by four patients. Our findings show that biologics are effective and well tolerated for treating very severe psoriasis, maintaining long-term effectiveness

 Pubmed Scholar sci-hub

Allergy 23 Feb. 2024.
Mouse eosinophil-associated ribonuclease-2 exacerbates the allergic response.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

J Eur Acad Dermatol Venereol Mar. 2024.
Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.

Baricitinib demonstrated a high level of maintenance of efficacy over 104 weeks in patients with severe AA. Efficacy increased in Week-52 mixed responders, illustrating that long-term treatment is necessary to observe maximum benefit in some patients. No new safety signals were observed.

 Pubmed Scholar sci-hub

Am J Hematol 23 Feb. 2024.
Clinical characteristics, treatment patterns, and outcomes of cytotoxic cutaneous T-cell lymphomas.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Skin Res Technol Mar. 2024.
Effects of Siegesbeckia herba extract against particulate matter 10 (PM ) in skin barrier-disrupted mouse models.

This study elucidated the therapeutic effects of SHE against PM in skin barrier-disrupted mouse models.

 Pubmed Scholar sci-hub

Front Med (Lausanne) . 2024.
Sirolimus treatment for intractable lymphatic anomalies: an open-label, single-arm, multicenter, prospective trial.

Sirolimus can reduce the lymphatic tissue volume in LAs and may lead to improvements in clinical symptoms and QOL.

 Pubmed Scholar sci-hub

JAAD Case Rep Mar. 2024.
Treatment of palmoplantar keratoderma in a patient with ichthyosis with topical tapinarof.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Exp Dermatol Feb. 2024.
Patients suffering from dystrophic epidermolysis bullosa are prone to developing autoantibodies against skin proteins: A longitudinal confirmational study.

Most patients showed reactivity to Type XVII collagen/linear IgA bullous dermatosis autoantigen (n = 5; 33%), followed by BP230 (n = 4; 27%), Type VII collagen (n = 4; 27%) and laminin-332 (n = 1; 7%). The pathogenicity of these autoantibodies remains a subject for future experiments

 Pubmed Scholar sci-hub

Exp Dermatol Feb. 2024.
NB-UVB and azathioprine combined therapy for patients with non-segmental vitiligo.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Sci Rep 22 Feb. 2024.
Topical minoxidil and dietary supplement for the treatment of chemotherapy-induced alopecia in childhood: a retrospective cohort study.

3%) patients reported mild and self-limiting adverse events. In conclusion, our study shows that minoxidil and CYP administration represent viable treatment options for pediatric CIA

 Pubmed Scholar sci-hub

Br Dent J Feb. 2024.
The management of pemphigus vulgaris and mucous membrane pemphigoid in a joint oral medicine and dermatology clinic: a five-year narrative review.

This report outlines the multisite nature of AIBDs and the range of topical and systemic treatments that were employed to achieve adequate disease control and optimise outcomes for patients. We reflect on the experiential benefits of this multidisciplinary clinic extended beyond immediate patient benefits to areas such as specialist training, both from a dermatologist's and oral physician's perspective

 Pubmed Scholar sci-hub

Exp Hematol Oncol 22 Feb. 2024.
Cirrhotic-extracellular matrix attenuates aPD-1 treatment response by initiating immunosuppressive neutrophil extracellular traps formation in hepatocellular carcinoma.

Cirrhotic-ECM modulated a NETs enriched TME in HCC, produced an immune suppressive TME and weakened ICI efficiency. Col1 receptor DDR1 could be a potential target synergically used with ICI to overcome ECM mediated ICI resistance. These provide a mechanical insight and novel strategy to overcome the ICI resistance of HCC.

 Pubmed Scholar sci-hub

RMD Open 22 Feb. 2024.
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL.

Bimekizumab demonstrated a safety profile consistent with previous reports; no new safety signals were identified. Sustained efficacy was observed from week 16 to 52.

 Pubmed Scholar sci-hub

J Am Acad Dermatol 20 Feb. 2024.
Negative impact of comorbidities on all-cause mortality of psoriasis patients is partially alleviated by biologic treatment: A real-world, case-control study.

Hepatic injury, psychiatric affective disorders and cardiovascular disease were major determinants of overall survival in psoriasis. Biologic therapy was associated with a reduced mortality risk.

 Pubmed Scholar sci-hub

J Dermatolog Treat Dec. 2024.
Successful treatment of acrodermatitis continua of Hallopeau by TYK2 inhibitor with every other day.

Sorry! No treatment pearl could be fetched.

 Pubmed Scholar sci-hub

Pediatr Dermatol 22 Feb. 2024.
Treatment of congenital Langerhans cell histiocytosis with cobimetinib.

After the failure of first-line (vinblastine and prednisolone) and second-line (vincristine and cytarabine) therapies, treatment with cobimetinib, a mitogen-activated protein kinase (MEK) inhibitor, led to the remission of disease and a sustained response after 11 months of ongoing treatment. Protein kinase inhibitors targeting BRAF or MEK could represent a promising future therapeutic option, also in children with LCH

 Pubmed Scholar sci-hub

J Cosmet Dermatol 22 Feb. 2024.
Efficacy and safety of bipolar fractional radiofrequency vs. 2940-nm Er:YAG ablative fractional laser in striae distensae treatment: A split abdomen study.

The efficacy and safety of bipolar FRF treatment are comparable to those of 2940-nm Er:YAG AFL treatment, providing an alternative and effective treatment for SD.

 Pubmed Scholar sci-hub

Int Wound J Mar. 2024.
First clinical evaluation of the safety and efficacy of tarumase for the debridement of venous leg ulcers.

As the concentration of tarumase was escalated, trends towards faster and improved effectiveness of wound debridement were observed, especially in patients with significant slough at baseline. Trends towards faster rates of healing were also noted based on observations of increased granulation tissue, increased linear healing and reduction in surface area over the 4-week treatment period

 Pubmed Scholar sci-hub